FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Cells / Treatment of Naturally Occurring Tendon Disease with Allogen...
Cells2023; 12(21); 2513; doi: 10.3390/cells12212513

Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses.

Abstract: The treatment of tendinopathies with multipotent mesenchymal stromal cells (MSCs) is a promising option in equine and human medicine. However, conclusive clinical evidence is lacking. The purpose of this study was to gain insight into clinical treatment efficacy and to identify suitable outcome measures for larger clinical studies. Fifteen horses with early naturally occurring tendon disease were assigned to intralesional treatment with allogeneic adipose-derived MSCs suspended in serum or with serum alone through block randomization (dosage adapted to lesion size). Clinicians and horse owners remained blinded to the treatment during 12 months (seven horses per group) and 18 months (seven MSC-group and five control-group horses) of follow-up including clinical examinations and diagnostic imaging. Clinical inflammation, lameness, and ultrasonography scores improved more over time in the MSC group. The lameness score difference significantly improved in the MSC group compared with the control group after 6 months. In the MSC group, five out of the seven horses were free of re-injuries and back to training until 12 and 18 months. In the control group, three out of the seven horses were free of re-injuries until 12 months. These results suggest that MSCs are effective for the treatment of early-phase tendon disease and provide a basis for a larger controlled study.
Get Full Text
Publication Date: 2023-10-24 PubMed ID: 37947591PubMed Central: PMC10650642DOI: 10.3390/cells12212513Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Randomized Controlled Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article dives into the impactful use of stem cells, particularly multipotent mesenchymal stromal cells (MSCs), in treating tendon disease in horses. The preliminary results of this randomized, controlled, triple-blinded pilot study have shown that MSCs are potentially effective for treating early-stage tendon disease, hinting at potential applications in equine and human medicine.

Objective of the Study

  • The principal motivation behind this research was to explore the potential effectiveness of multipotent mesenchymal stromal cells (MSCs) in curing naturally occurring tendon disorders in horses. Additionally, the study sought to identify ideal outcomes that would serve as benchmark indicatives for future larger-scale investigations.

Methodology

  • The research included fifteen horses suffering from early-stage tendon diseases. The treatment involved an intralesional application of MSCs derived from adipose (fat) tissue which were suspended in serum.
  • The study employed a block randomization method to assign the treatment to the horses. The clinician, as well as the horse owners, remained unaware of the administration during the period of 12 and 18 months of follow-up.
  • In the follow-up period, regular clinical check-ups and diagnostic imaging were conducted to track the effect of the treatment.

Results

  • The study observed significant improvements over time in the treated group, marked by reduced clinical inflammation, lameness, and improved ultrasonography scores.
  • The difference in lameness scores between the MSC-treated group and the control group showed significant improvement after six months in the former.
  • Further, in the MSC-treated group, 5 out of 7 horses were free of re-injuries and had returned to training up to 12 and 18 months. In contrast, within the control group, only 3 out of 7 horses were free of re-injuries after a similar period.

Conclusion

  • Consequently, these findings suggest that multipotent mesenchymal stromal cells (MSCs) could be promising in treating early-stage tendon diseases. Consequently, the results of this pilot study lay a foundation for larger controlled studies in the future.

Cite This Article

APA
Burk J, Wittenberg-Voges L, Schubert S, Horstmeier C, Brehm W, Geburek F. (2023). Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses. Cells, 12(21), 2513. https://doi.org/10.3390/cells12212513

Publication

Cells
ISSN: 2073-4409
NlmUniqueID: 101600052
Country: Switzerland
Language: English
Volume: 12
Issue: 21
PII: 2513

Researcher Affiliations

Burk, Janina
  • Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Wittenberg-Voges, Liza
  • Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Bünteweg 9, 30559 Hannover, Germany.
Schubert, Susanna
  • Institute of Human Genetics, University of Leipzig Medical Center, Philipp-Rosenthal-Strasse 55, 04103 Leipzig, Germany.
Horstmeier, Carolin
  • Department for Horses, Veterinary Teaching Hospital, University of Leipzig, An den Tierkliniken 21, 04103 Leipzig, Germany.
Brehm, Walter
  • Department for Horses, Veterinary Teaching Hospital, University of Leipzig, An den Tierkliniken 21, 04103 Leipzig, Germany.
Geburek, Florian
  • Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Bünteweg 9, 30559 Hannover, Germany.

MeSH Terms

  • Humans
  • Horses
  • Animals
  • Pilot Projects
  • Lameness, Animal / therapy
  • Lameness, Animal / pathology
  • Reinjuries
  • Horse Diseases / therapy
  • Horse Diseases / pathology
  • Mesenchymal Stem Cell Transplantation / veterinary
  • Mesenchymal Stem Cells / pathology
  • Tendons / pathology
  • Hematopoietic Stem Cell Transplantation

Grant Funding

  • 491094227 / Deutsche Forschungsgemeinschaft
  • University of Veterinary Medicine Hannover, Foundation

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 67 references
  1. Smith R.K., Korda M., Blunn G.W., Goodship A.E.. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet. J. 2003;35:99–102.
    doi: 10.2746/042516403775467388pubmed: 12553472google scholar: lookup
  2. Stewart M.C., Stewart A.A.. Mesenchymal stem cells: Characteristics, sources, and mechanisms of action. Vet. Clin. N. Am. Equine Pract. 2011;27:243–261.
    doi: 10.1016/j.cveq.2011.06.004pubmed: 21872757google scholar: lookup
  3. De Schauwer C., Van de Walle G.R., Van Soom A., Meyer E.. Mesenchymal stem cell therapy in horses: Useful beyond orthopedic injuries?. Vet. Q. 2013;33:234–241.
    doi: 10.1080/01652176.2013.800250pubmed: 23697553google scholar: lookup
  4. Voga M., Adamic N., Vengust M., Majdic G.. Stem Cells in Veterinary Medicine-Current State and Treatment Options. Front. Vet. Sci. 2020;7:278.
    doi: 10.3389/fvets.2020.00278pmc: PMC7326035pubmed: 32656249google scholar: lookup
  5. Cequier A., Sanz C., Rodellar C., Barrachina L.. The Usefulness of Mesenchymal Stem Cells beyond the Musculoskeletal System in Horses. Animals 2021;11:931.
    doi: 10.3390/ani11040931pmc: PMC8064371pubmed: 33805967google scholar: lookup
  6. Prządka P., Buczak K., Frejlich E., Gąsior L., Suliga K., Kiełbowicz Z.. The Role of Mesenchymal Stem Cells (MSCs) in Veterinary Medicine and Their Use in Musculoskeletal Disorders. Biomolecules 2021;11:1141.
    doi: 10.3390/biom11081141pmc: PMC8391453pubmed: 34439807google scholar: lookup
  7. Barrett J.G., MacDonald E.S.. Use of Biologics and Stem Cells in the Treatment of Other Inflammatory Diseases in the Horse. Vet. Clin. N. Am. Equine Pract. 2023. Online ahead of print.
    pubmed: 37607855
  8. Watts A.E.. Use of Stem Cells for the Treatment of Musculoskeletal Injuries in Horses. Vet. Clin. N. Am. Equine Pract. 2023. Online ahead of print.
    doi: 10.1016/j.cveq.2023.07.003pubmed: 37625917google scholar: lookup
  9. Godwin E.E., Young N.J., Dudhia J., Beamish I.C., Smith R.K.. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. Equine Vet. J. 2012;44:25–32.
    doi: 10.1111/j.2042-3306.2011.00363.xpubmed: 21615465google scholar: lookup
  10. Beerts C., Suls M., Broeckx S.Y., Seys B., Vandenberghe A., Declercq J., Duchateau L., Vidal M.A., Spaas J.H.. Tenogenically Induced Allogeneic Peripheral Blood Mesenchymal Stem Cells in Allogeneic Platelet-Rich Plasma: 2-Year Follow-up after Tendon or Ligament Treatment in Horses. Front. Vet. Sci. 2017;4:158.
    doi: 10.3389/fvets.2017.00158pmc: PMC5622984pubmed: 29018808google scholar: lookup
  11. Salz R.O., Elliott C.R.B., Zuffa T., Bennet E.D., Ahern B.J.. Treatment of racehorse superficial digital flexor tendonitis: A comparison of stem cell treatments to controlled exercise rehabilitation in 213 cases. Equine Vet. J. 2023;55:979–987.
    doi: 10.1111/evj.13922pubmed: 36604727google scholar: lookup
  12. Schnabel L.V., Lynch M.E., van der Meulen M.C., Yeager A.E., Kornatowski M.A., Nixon A.J.. Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. J. Orthop. Res. 2009;27:1392–1398.
    doi: 10.1002/jor.20887pubmed: 19350658google scholar: lookup
  13. Crovace A., Lacitignola L., Rossi G., Francioso E.. Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon. Vet. Med. Int. 2010;2010:250978.
    doi: 10.4061/2010/250978pmc: PMC2859019pubmed: 20445779google scholar: lookup
  14. Carvalho Ade M., Badial P.R., Álvarez L.E., Yamada A.L., Borges A.S., Deffune E., Hussni C.A., Garcia Alves A.L.. Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: A randomized controlled trial. Stem Cell Res. Ther. 2013;4:85.
    doi: 10.1186/scrt236pmc: PMC3854756pubmed: 23876512google scholar: lookup
  15. Depuydt E., Broeckx S.Y., Van Hecke L., Chiers K., Van Brantegem L., van Schie H., Beerts C., Spaas J.H., Pille F., Martens A.. The Evaluation of Equine Allogeneic Tenogenic Primed Mesenchymal Stem Cells in a Surgically Induced Superficial Digital Flexor Tendon Lesion Model. Front. Vet. Sci. 2021;8:641441.
    doi: 10.3389/fvets.2021.641441pmc: PMC7973085pubmed: 33748217google scholar: lookup
  16. Geburek F., Roggel F., van Schie H.T.M., Beineke A., Estrada R., Weber K., Hellige M., Rohn K., Jagodzinski M., Welke B.. Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: A controlled experimental trial. Stem Cell Res. Ther. 2017;8:129.
    doi: 10.1186/s13287-017-0564-8pmc: PMC5460527pubmed: 28583184google scholar: lookup
  17. Ahrberg A.B., Horstmeier C., Berner D., Brehm W., Gittel C., Hillmann A., Josten C., Rossi G., Schubert S., Winter K.. Effects of mesenchymal stromal cells versus serum on tendon healing in a controlled experimental trial in an equine model. BMC Musculoskelet. Disord. 2018;19:230.
    doi: 10.1186/s12891-018-2163-ypmc: PMC6052633pubmed: 30021608google scholar: lookup
  18. Lui P.P.Y., Maffulli N., Rolf C., Smith R.K.W.. What are the validated animal models for tendinopathy?. Scand. J. Med. Sci. Sports. 2011;21:3–17.
    doi: 10.1111/j.1600-0838.2010.01164.xpubmed: 20673247google scholar: lookup
  19. Patterson-Kane J.C., Becker D.L., Rich T.. The pathogenesis of tendon microdamage in athletes: The horse as a natural model for basic cellular research. J. Comp. Pathol. 2012;147:227–247.
    doi: 10.1016/j.jcpa.2012.05.010pubmed: 22789861google scholar: lookup
  20. Meeremans M., Van de Walle G.R., Van Vlierberghe S., De Schauwer C.. The Lack of a Representative Tendinopathy Model Hampers Fundamental Mesenchymal Stem Cell Research. Front. Cell Dev. Biol. 2021;9:651164.
    doi: 10.3389/fcell.2021.651164pmc: PMC8126669pubmed: 34012963google scholar: lookup
  21. Luo J., Wang Z., Tang C., Yin Z., Huang J., Ruan D., Fei Y., Wang C., Mo X., Li J.. Animal model for tendinopathy. J. Orthop. Translat. 2023;42:43–56.
    doi: 10.1016/j.jot.2023.06.005pmc: PMC10450357pubmed: 37637777google scholar: lookup
  22. Smith R.K., Werling N.J., Dakin S.G., Alam R., Goodship A.E., Dudhia J.. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy. PLoS ONE 2013;8:e75697.
    doi: 10.1371/annotation/a30a4b87-8904-4510-b0a8-5b6ca6097f9apmc: PMC3783421pubmed: 24086616google scholar: lookup
  23. Schubert S., Brehm W., Hillmann A., Burk J.. Serum-free human MSC medium supports consistency in human but not in equine adipose-derived multipotent mesenchymal stromal cell culture. Cytometry A 2018;93:60–72.
    doi: 10.1002/cyto.a.23240pubmed: 28926198google scholar: lookup
  24. Paebst F., Piehler D., Brehm W., Heller S., Schroeck C., Tárnok A., Burk J.. Comparative immunophenotyping of equine multipotent mesenchymal stromal cells: An approach toward a standardized definition. Cytometry A 2014;85:678–687.
    doi: 10.1002/cyto.a.22491pubmed: 24894974google scholar: lookup
  25. Lang H.M., Schnabel L.V., Cassano J.M., Fortier L.A.. Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells. Vet. Surg. 2017;46:731–737.
    doi: 10.1111/vsu.12639pmc: PMC5493497pubmed: 28328147google scholar: lookup
  26. Müller M., Raabe O., Addicks K., Wenisch S., Arnhold S.. Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells. Cell Biol. Int. 2011;35:235–248.
    doi: 10.1042/CBI20090211pubmed: 21087205google scholar: lookup
  27. Smith R.K., McIlwraith C.W.. Consensus on equine tendon disease: Building on the 2007 Havemeyer symposium. Equine Vet J. 2012;44:2–6.
    doi: 10.1111/j.2042-3306.2011.00497.xpubmed: 22070097google scholar: lookup
  28. Geburek F., Lietzau M., Beineke A., Rohn K., Stadler P.M.. Effect of a single injection of autologous conditioned serum (ACS) on tendon healing in equine naturally occurring tendinopathies. Stem Cell Res. Ther. 2015;6:126.
    doi: 10.1186/s13287-015-0115-0pmc: PMC4513386pubmed: 26113022google scholar: lookup
  29. Genovese R.L., Rantanen N.W., Hauser M.L., Simpson B.S.. Diagnostic ultrasonography of equine limbs. Vet. Clin. N. Am. Equine Pract. 1986;2:145–226.
    doi: 10.1016/S0749-0739(17)30738-1pubmed: 3516322google scholar: lookup
  30. Rantanen N.W., Jorgensen J.S., Genovese R.L.. Ultrasonographic evaluation of the equine limb: Technique. In: Ross M.W., Dyson S.J., editors. Diagnosis and Management of Lameness in the Horse. 1st ed. Elsevier; St. Louis, MO, USA: 2003. pp. 166–188.
  31. Conze P., van Schie H.T., van Weeren R., Staszyk C., Conrad S., Skutella T., Hopster K., Rohn K., Stadler P., Geburek F.. Effect of autologous adipose tissue-derived mesenchymal stem cells on neovascularization of artificial equine tendon lesions. Regen. Med. 2014;9:743–757.
    doi: 10.2217/rme.14.55pubmed: 25431911google scholar: lookup
  32. Berner D., Brehm W., Gerlach K., Offhaus J., Scharner D., Burk J.. Variation in the MRI signal intensity of naturally occurring equine superficial digital flexor tendinopathies over a 12-month period. Vet. Rec. 2020;187:e53.
    doi: 10.1136/vr.105800pubmed: 32690762google scholar: lookup
  33. Carrade D.D., Affolter V.K., Outerbridge C.A., Watson J.L., Galuppo L.D., Buerchler S., Kumar V., Walker N.J., Borjesson D.L.. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions. Cytotherapy 2011;13:1180–1192.
    doi: 10.3109/14653249.2011.602338pubmed: 21899391google scholar: lookup
  34. Kol A., Wood J.A., Carrade Holt D.D., Gillette J.A., Bohannon-Worsley L.K., Puchalski S.M., Walker N.J., Clark K.C., Watson J.L., Borjesson D.L.. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses. Stem Cell Res. Ther. 2015;6:73.
    doi: 10.1186/s13287-015-0050-0pmc: PMC4446064pubmed: 25888916google scholar: lookup
  35. Williams L.B., Co C., Koenig J.B., Tse C., Lindsay E., Koch T.G.. Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media. Front. Vet. Sci. 2016;3:56.
    doi: 10.3389/fvets.2016.00056pmc: PMC4956649pubmed: 27500136google scholar: lookup
  36. Brandão J.S., Alvarenga M.L., Pfeifer J.P.H., Dos Santos V.H., Fonseca-Alves C.E., Rodrigues M., Laufer-Amorim R., Castillo J.A.L., Alves A.L.G.. Allogeneic mesenchymal stem cell transplantation in healthy equine superficial digital flexor tendon: A study of the local inflammatory response. Res. Vet. Sci. 2018;118:423–430.
    doi: 10.1016/j.rvsc.2018.03.012pubmed: 29715649google scholar: lookup
  37. Pezzanite L.M., Fortier L.A., Antczak D.F., Cassano J.M., Brosnahan M.M., Miller D., Schnabel L.V.. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res. Ther. 2015;6:54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  38. Owens S.D., Kol A., Walker N.J., Borjesson D.L.. Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses. Stem Cells Int. 2016;2016:5830103.
    doi: 10.1155/2016/5830103pmc: PMC5018342pubmed: 27648075google scholar: lookup
  39. Berglund A.K., Schnabel L.V.. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies. Equine Vet. J. 2017;49:539–544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  40. Barrachina L., Cequier A., Romero A., Vitoria A., Zaragoza P., Vázquez F.J., Rodellar C.. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: Effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility. Stem Cell Res. Ther. 2020;11:52.
    doi: 10.1186/s13287-020-1571-8pmc: PMC7006079pubmed: 32028995google scholar: lookup
  41. Joswig A.J., Mitchell A., Cummings K.J., Levine G.J., Gregory C.A., Smith R., Watts A.E.. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res. Ther. 2017;8:42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  42. Zhang J., Huang X., Wang H., Liu X., Zhang T., Wang Y., Hu D.. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res. Ther. 2015;6:234.
    doi: 10.1186/s13287-015-0240-9pmc: PMC4665863pubmed: 26620426google scholar: lookup
  43. Shah K., Shah N., Ghassemi F., Ly C., George T., Lutz C., Sumer H.. Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review. Stem Cells Int. 2022;2022:9589600.
    doi: 10.1155/2022/9589600pmc: PMC8926542pubmed: 35308830google scholar: lookup
  44. Rowland A.L., Burns M.E., Levine G.J., Watts A.E.. Preparation Technique Affects Recipient Immune Targeting of Autologous Mesenchymal Stem Cells. Front. Vet. Sci. 2021;8:724041.
    doi: 10.3389/fvets.2021.724041pmc: PMC8478329pubmed: 34595230google scholar: lookup
  45. Naskou M.C., Sumner S.M., Chocallo A., Kemelmakher H., Thoresen M., Copland I., Galipeau J., Peroni J.F.. Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells. Stem Cell Res. Ther. 2018;9:75.
    doi: 10.1186/s13287-018-0823-3pmc: PMC5863827pubmed: 29566772google scholar: lookup
  46. Seo J.P., Tsuzuki N., Haneda S., Yamada K., Furuoka H., Tabata Y., Sasaki N.. Comparison of allogeneic platelet lysate and fetal bovine serum for in vitro expansion of equine bone marrow-derived mesenchymal stem cells. Res. Vet. Sci. 2013;95:693–698.
    doi: 10.1016/j.rvsc.2013.04.024pubmed: 23683731google scholar: lookup
  47. Russell K.A., Koch T.G.. Equine platelet lysate as an alternative to fetal bovine serum in equine mesenchymal stromal cell culture—Too much of a good thing?. Equine Vet. J. 2016;48:261–264.
    doi: 10.1111/evj.12440pubmed: 25772755google scholar: lookup
  48. Hendijani F.. Explant culture: An advantageous method for isolation of mesenchymal stem cells from human tissues. Cell Prolif. 2017;50:e12334.
    doi: 10.1111/cpr.12334pmc: PMC6529062pubmed: 28144997google scholar: lookup
  49. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj Horwitz E.. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
    doi: 10.1080/14653240600855905pubmed: 16923606google scholar: lookup
  50. Geburek F., Mundle K., Conrad S., Hellige M., Walliser U., van Schie H.T., van Weeren R., Skutella T., Stadler P.M.. Tracking of autologous adipose tissue-derived mesenchymal stromal cells with in vivo magnetic resonance imaging and histology after intralesional treatment of artificial equine tendon lesions-a pilot study. Stem Cell Res. Ther. 2016;7:21.
    doi: 10.1186/s13287-016-0281-8pmc: PMC4736260pubmed: 26830812google scholar: lookup
  51. Burk J., Berner D., Brehm W., Hillmann A., Horstmeier C., Josten C., Paebst F., Rossi G., Schubert S., Ahrberg A.B.. Long-Term Cell Tracking Following Local Injection of Mesenchymal Stromal Cells in the Equine Model of Induced Tendon Disease. Cell Transplant. 2016;25:2199–2211.
    doi: 10.3727/096368916X692104pubmed: 27392888google scholar: lookup
  52. Espina M., Jülke H., Brehm W., Ribitsch I., Winter K., Delling U.. Evaluation of transport conditions for autologous bone marrow-derived mesenchymal stromal cells for therapeutic application in horses. PeerJ 2016;4:e1773.
    doi: 10.7717/peerj.1773pmc: PMC4806605pubmed: 27019778google scholar: lookup
  53. Dyson S.J.. Medical management of superficial digital flexor tendonitis: A comparative study in 219 horses (1992–2000). Equine Vet. J. 2004;36:415–419.
    doi: 10.2746/0425164044868422pubmed: 15253082google scholar: lookup
  54. Jiang L., Lu J., Chen Y., Lyu K., Long L., Wang X., Liu T., Li S.. Mesenchymal stem cells: An efficient cell therapy for tendon repair (Review). Int. J. Mol. Med. 2023;52:70.
    doi: 10.3892/ijmm.2023.5273pmc: PMC10373123pubmed: 37387410google scholar: lookup
  55. Peroni J.F., Borjesson D.L.. Anti-inflammatory and immunomodulatory activities of stem cells. Vet. Clin. N. Am. Equine Pract. 2011;27:351–362.
    doi: 10.1016/j.cveq.2011.06.003pubmed: 21872763google scholar: lookup
  56. Yi T., Song S.U.. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharm. Res. 2012;35:213–221.
    doi: 10.1007/s12272-012-0202-zpubmed: 22370776google scholar: lookup
  57. Shen H., Kormpakis I., Havlioglu N., Linderman S.W., Sakiyama-Elbert S.E., Erickson I.E., Zarembinski T., Silva M.J., Gelberman R.H., Thomopoulos S.. The effect of mesenchymal stromal cell sheets on the inflammatory stage of flexor tendon healing. Stem Cell Res. Ther. 2016;7:144.
    doi: 10.1186/s13287-016-0406-0pmc: PMC5039894pubmed: 27677963google scholar: lookup
  58. Xu H., Zhu Y., Hsiao A.W., Xu J., Tong W., Chang L., Zhang X., Chen Y.F., Li J., Chen W.. Bioactive glass elicited stem cell-derived extracellular vesicles regulate M2 macrophage polarization and angiogenesis to improve tendon regeneration and functional recovery. Biomaterials 2023;294:121998.
    doi: 10.1016/j.biomaterials.2023.121998pubmed: 36641814google scholar: lookup
  59. Ohberg L., Alfredson H.. Ultrasound guided sclerosis of neovessels in painful chronic Achilles tendinosis: Pilot study of a new treatment. Br. J. Sports Med. 2002;36:173–177.
    doi: 10.1136/bjsm.36.3.173pmc: PMC1724500pubmed: 12055110google scholar: lookup
  60. Kristoffersen M., Ohberg L., Johnston C., Alfredson H.. Neovascularisation in chronic tendon injuries detected with colour Doppler ultrasound in horse and man: Implications for research and treatment. Knee Surg. Sports Traumatol. Arthrosc. 2005;13:505–508.
    doi: 10.1007/s00167-005-0648-3pubmed: 15864547google scholar: lookup
  61. Hatazoe T., Endo Y., Iwamoto Y., Korosue K., Kuroda T., Inoue S., Murata D., Hobo S., Misumi K.. A study of the distribution of color Doppler flows in the superficial digital flexor tendon of young Thoroughbreds during their training periods. J. Equine Sci. 2015;26:99–104.
    doi: 10.1294/jes.26.99pmc: PMC4739139pubmed: 26858574google scholar: lookup
  62. Ceserani V., Ferri A., Berenzi A., Benetti A., Ciusani E., Pascucci L., Bazzucchi C., Coccè V., Bonomi A., Pessina A.. Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells. Vasc. Cell. 2016;8:3.
    doi: 10.1186/s13221-016-0037-3pmc: PMC4991117pubmed: 27547374google scholar: lookup
  63. Siadat S.M., Zamboulis D.E., Thorpe C.T., Ruberti J.W., Connizzo B.K.. Tendon Extracellular Matrix Assembly, Maintenance and Dysregulation Throughout Life. Adv. Exp. Med. Biol. 2021;1348:45–103.
    pubmed: 34807415
  64. Birch H.L., Thorpe C.T., Rumian A.P.. Specialisation of extracellular matrix for function in tendons and ligaments. Muscles Ligaments Tendons J. 2013;3:12–22.
    doi: 10.32098/mltj.01.2013.04pmc: PMC3676159pubmed: 23885341google scholar: lookup
  65. Hammer N., Huster D., Fritsch S., Hädrich C., Koch H., Schmidt P., Sichting F., Wagner M.F., Boldt A.. Do cells contribute to tendon and ligament biomechanics?. PLoS ONE 2014;9:e105037.
    doi: 10.1371/journal.pone.0105037pmc: PMC4134275pubmed: 25126746google scholar: lookup
  66. Ehrle A., Lilge S., Clegg P.D., Maddox T.W.. Equine flexor tendon imaging part 1: Recent developments in ultrasonography, with focus on the superficial digital flexor tendon. Vet. J. 2021;278:105764.
    doi: 10.1016/j.tvjl.2021.105764pubmed: 34678500google scholar: lookup
  67. van Schie H.T., Bakker E.M., Jonker A.M., van Weeren P.R.. Computerized ultrasonographic tissue characterization of equine superficial digital flexor tendons by means of stability quantification of echo patterns in contiguous transverse ultrasonographic images. Am. J. Vet. Res. 2003;64:366–375.
    doi: 10.2460/ajvr.2003.64.366pubmed: 12661879google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.